Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Dr Crowther and colleagues1 reported that the occurrence of a secondary, composite
variable defined as "death or substantial motor dysfunction at a corrected
age of 2 years" was significantly lower in the group exposed to magnesium
sulfate. None of the individual outcomes, including cerebral palsy, was significantly
different between the groups, although each was less common in the magnesium
Mittendorf R, Lee K, Roizen NJ, Pryde PG. Magnesium Sulfate for Preterm Neuroprotection. JAMA. 2004;291(8):940-941. doi:10.1001/jama.291.8.940-c